BHC - Bausch Health Companies Inc.

NYSE - NYSE Delayed Price. Currency in USD
+0.62 (+2.54%)
At close: 4:00PM EDT

25.00 0.00 (0.00%)
After hours: 4:38PM EDT

Stock chart is not supported by your current browser
Previous Close24.38
Bid25.00 x 800
Ask25.00 x 800
Day's Range24.40 - 25.16
52 Week Range17.20 - 28.45
Avg. Volume3,818,443
Market Cap8.797B
Beta (3Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)-4.61
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target Est30.93
Trade prices are not sourced from all markets
  • TheStreet.com2 days ago

    Bausch Health Gains on Debt Reduction, Psoriasis-Lotion Launch

    gained on Tuesday after the health-sciences company said it had reduced its debt outstanding and introduced a new psoriasis-treatment lotion. The Laval, Quebec, company said it had paid down an additional $100 million of debt using cash from operations, eliminating any additional "mandatory amortization" for its fiscal 2020 first quarter. Calling the drug one of its "significant seven" -- a collection of products that could garner a predicted $1 billion in sales through 2024 -- Bausch Health expects Duobrii to be a strong revenue driver.

  • Benzinga2 days ago

    Bausch Sees Clearer With Less Debt

    Bausch Health Companies Inc (NYSE: BHC ) jumped 3% on Tuesday after the company announced it has taken a major stride in paying down its massive debt load. Bausch, which changed its name from Valeant Pharmaceuticals ...

  • Zacks2 days ago

    Allergan Up As Analyst Statement Sparks Business Split Rumors

    Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.

  • MarketWatch2 days ago

    Bausch Health to pay down more debt this week, stock rallies

    Bausch Health Companies Inc. said Tuesday it will pay down an additional $100 million worth of debt this week, which will eliminate all mandatory amortization for the first quarter of 2020. The stock rose 1.9% in premarket trading. The maker of pharmaceutical, medical-device and over-the-counter products said it will use cash generated from operations to pay down the senior secured terms loans. The stock has lost 1.6% over the past three months but has rallied 28.6% year to date through Monday, while the S&P 500 has gained 17.5% this year.

  • CNW Group2 days ago

    Bausch Health To Reduce Debt By Additional $100 Million Using Cash Generated From Operations

    LAVAL, Quebec , June 25, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it put in notice to pay down an additional $100 million of its senior secured term loans this week, using cash generated from operations. After this payment, the Company will have eliminated all mandatory amortization for the first quarter of 2020. Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products.

  • PR Newswire2 days ago

    Bausch Health Announces U.S. Launch of DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults

    LAVAL, Quebec, June 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that DUOBRII™ (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, will be available commercially to health care professionals starting this week. Approved by the U.S. Food and Drug Administration on April 25, 2019, DUOBRII is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation. "The launch of DUOBRII marks the fifth innovative therapy that Ortho Dermatologics has brought forward within the last 30 months," said Bill Humphries, president, Ortho Dermatologics.

  • Barrons.com3 days ago

    Another Women’s Libido Drug, Vyleesi, Won FDA Approval. Stock Investors Aren’t Happy.

    It has been a roller-coaster day on the market for the two companies behind Vyleesi, an injection that received Food and Drug Administration approval last week to treat low sex drive in women. The drug’s approval received significant news coverage, and much of it focused on the controversy that surrounded the other drug approved for low sex drive in women, Addyi, which has struggled on the market and drawn criticism for its potential side effects. The approval of Addyi, marketed by Sprout Pharmaceuticals, drew significant attention in 2015, and led to the $1 billion acquisition of Sprout by (BHC) now (BHC) (BHC).

  • Is Bausch Health (BHC) a Great Value Stock Right Now?
    Zacks3 days ago

    Is Bausch Health (BHC) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%
    Zacks6 days ago

    Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%

    Bausch Health (BHC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • PR Newswire8 days ago

    Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses Now Available In the United States

    BRIDGEWATER, N.J., June 19, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first and only multifocal toric lens available as a standard offering in the eye care professional's fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the company's unique 3-Zone Progressive™ multifocal design with the stability of its OpticAlign® toric design to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam.

  • Barclays Has New Plays for Healthcare Fans
    SmarterAnalyst15 days ago

    Barclays Has New Plays for Healthcare Fans

    Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays'  has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Conatus (CNAT) Stock Price Could Hit Zero * Tesla (TSLA) Scrambles to Restore Faith; Wedbush Remains Cautions on the Stock * Micron (MU) Stock Has a New Bull * Has Roku Stock Price Hit Its Peak?

  • Markit16 days ago

    See what the IHS Markit Score report has to say about Bausch Health Companies Inc.

    Bausch Health Companies Inc NYSE:BHCView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BHC with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BHC. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BHC totaled $1.20 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. BHC credit default swap spreads are near the lowest level of the last three years and indicate the market's continued positive perception of the company's credit worthiness.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 4 Predictable Guru Stocks
    GuruFocus.com21 days ago

    4 Predictable Guru Stocks

    Ross Stores makes the list

  • Why Is Bausch (BHC) Down 16.2% Since Last Earnings Report?
    Zacks22 days ago

    Why Is Bausch (BHC) Down 16.2% Since Last Earnings Report?

    Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Biotech Sector Could Enter Bear Market
    Investopedia23 days ago

    Biotech Sector Could Enter Bear Market

    Institutional players are abandoning biotech funds at a rapid pace, raising the odds that the sector will enter a bear market.

  • PR Newswire29 days ago

    Bausch Health Companies Announces Participation in Upcoming Investor Conferences

    LAVAL, Quebec , May 29, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that the Company will participate in two investor conferences in June. Paul S. Herendeen , executive ...

  • CNW Grouplast month

    Bausch Health Announces Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes

    LAVAL, Quebec , May 23, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today the results to date of its pending cash tender offers (collectively, the "Tender Offers," and each offer to purchase a series of notes individually, a "Tender Offer") to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of its outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date for the Tender Offers on May 24, 2019 (the "Early Settlement Date"). The terms and conditions of the Tender Offers are described in an Offer to Purchase dated May 9, 2019 (as it may be amended or supplemented from time to time, the "Offer to Purchase") and the related Letter of Transmittal.

  • Better Turnaround Play: Bausch Health Companies or Teva Pharmaceutical Industries
    Motley Foollast month

    Better Turnaround Play: Bausch Health Companies or Teva Pharmaceutical Industries

    Which of these fallen stars has the more compelling comeback story?